Peptide purity and the certificate of analysis: how to read a COA
TL;DR
- A certificate of analysis is the lab receipt for a specific peptide batch, covering purity, identity, sterility, and endotoxin level.
- Look for greater than 98 percent purity by HPLC, mass spectrometry identity confirmation, and a matching batch number on your vial.
- A clean COA on one batch does not mean every batch is clean — verification only works when batch numbers match.
What it is
A certificate of analysis, or COA, is a third-party lab document that reports what is actually in a vial of compounded peptide. It is the receipt the pharmacy or manufacturer provides to show the batch passed identity and quality testing. A complete COA covers four things: purity (in plain English: how much of the vial is the target peptide versus impurities), identity (in plain English: confirming the molecule is what the label says), sterility (in plain English: no living microbes), and endotoxin level (in plain English: no harmful bacterial fragments). Without these, a compounded peptide is unverified.
How it works
Think of a COA the way you would think of a nutrition label combined with a fingerprint. HPLC, which stands for high performance liquid chromatography (in plain English: a fingerprint reader for molecules), separates everything in the vial and measures how much of each piece is present. Mass spectrometry (in plain English: a scale that weighs individual molecules) then confirms the main peak weighs exactly what the target peptide should weigh. Sterility testing checks for live microbes. The endotoxin test, often called LAL, checks for bacterial debris. Together, these tests describe one specific batch.
Who asks about it
Patients new to compounded peptides almost always ask, “How do I know what is in this?” Clinicians ask the same question on behalf of their patients. The COA is the document that answers it — when the seller provides a real one.
What the research says
USP General Chapter <797> sets the sterility framework U.S. compounding pharmacies follow. FDA guidance documents on compounded preparations describe identity, strength, quality, and purity expectations for 503A and 503B pharmacies. Independent surveys of gray-market peptide sellers, published in pharmacy and toxicology literature, have repeatedly found mislabeled purity, missing endotoxin testing, and reused COAs across unrelated batches. The pattern is consistent: regulated 503A pharmacies produce verifiable COAs; gray-market sources often do not.
What to know before considering it
When reviewing a COA, four checks matter. First, is the batch number on the COA the same number printed on your vial? Second, does HPLC purity report greater than 98 percent? Third, does mass spectrometry confirm the correct molecular weight? Fourth, are sterility and endotoxin tests both present, with passing results from an accredited lab? If any of these are missing or do not match, the COA is not doing its job.
The Halftime POV
A COA is not a marketing document. It is a verification document. The goal is not a pretty PDF — it is matching the batch number on your vial to a lab report that proves what is in it. Working with a 503A pharmacy that publishes batch-specific COAs is the cleanest version of this process.
Related reading:
FAQ
Q: What is a peptide certificate of analysis? A: A COA is a lab document that reports the purity, identity, sterility, and endotoxin level of a specific peptide batch. It is the receipt for what is in the vial.
Q: What purity should a compounded peptide be? A: Reputable 503A pharmacies typically report greater than 98 percent purity by HPLC for compounded peptides, with mass spectrometry confirmation of identity.
Q: Does a clean COA mean every vial is safe? A: No. A COA reports one batch. Verification of the batch number on your vial against the COA is what closes the loop.
Q: Where do gray-market sellers fall short on COAs? A: Common issues include stale COAs from old batches, COAs from unrelated products, missing sterility data, or no batch number at all.
Disclaimer
This article is educational and is not medical advice. Compounded medications are not FDA-approved. Clinical outcomes depend on individual factors and require physician evaluation. Results vary. Halftime Health is launching soon — join the waitlist to get updates.
Get updates
Halftime Health is launching soon. Join the waitlist for updates.
Sources
- United States Pharmacopeia. “General Chapter <797> Pharmaceutical Compounding — Sterile Preparations.” USP, 2023. https://www.usp.org/compounding/general-chapter-797
- U.S. Food and Drug Administration. “Compounding Laws and Policies.” FDA, 2024. https://www.fda.gov/drugs/human-drug-compounding/compounding-laws-and-policies
- Cohen PA, et al. “Mislabeling and quality issues in compounded and gray-market peptide products.” Clinical Toxicology, 2022. https://pubmed.ncbi.nlm.nih.gov/34842490/
